Mersana Therapeutics, Inc. announced that after a strategic evaluation the Company will prioritize its resources to focus on the advancement of XMT-1536, a first-in-class ADC candidate targeting NaPi2b. As a result, Mersana and its partner, Takeda, plan to terminate the co-development collaboration for XMT-1522. Mersana will work with investigators to ensure that patients benefitting from XMT-1522 will continue to have access to the therapy as needed.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
2.145 USD | +3.12% |
|
+11.52% | -8.19% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.19% | 25Cr | |
+20.69% | 13TCr | |
+24.67% | 12TCr | |
+25.44% | 2.77TCr | |
-17.99% | 2.03TCr | |
-15.17% | 1.68TCr | |
-14.78% | 1.56TCr | |
+12.87% | 1.48TCr | |
-47.10% | 1.46TCr | |
+56.12% | 1.44TCr |
- Stock Market
- Equities
- MRSN Stock
- News Mersana Therapeutics, Inc.
- Mersana Therapeutics, Inc. and Takeda Plan to Terminate the Co-Development Collaboration for XMT-1522